TR200002145T2 - İnsan IL-12'ye karşı antikorlar - Google Patents

İnsan IL-12'ye karşı antikorlar

Info

Publication number
TR200002145T2
TR200002145T2 TR2000/02145T TR200002145T TR200002145T2 TR 200002145 T2 TR200002145 T2 TR 200002145T2 TR 2000/02145 T TR2000/02145 T TR 2000/02145T TR 200002145 T TR200002145 T TR 200002145T TR 200002145 T2 TR200002145 T2 TR 200002145T2
Authority
TR
Turkey
Prior art keywords
human
antibodies
heterodimer
specific
bioactivity
Prior art date
Application number
TR2000/02145T
Other languages
English (en)
Inventor
Kent Gately Maurcie
Howard Presky David
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22106938&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200002145(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of TR200002145T2 publication Critical patent/TR200002145T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Mevcut bulus, insan IL-12 biyoaktivitesinin nötralize edilmesinde bilinen heterodimere özgü IL-12 monoklonal antikorlarindan daha yüksek bir potansiyel ve verimlilikle karakterize olan p75e özgü anti-insan IL-12 antikorlari ile ilgilidir. heterodimere özgü antikorlari, insan IL-12 p75 heterodimerin bir veya daha fazla epitopunu tanir fakat tek basina p40 alt ünitesini baglamaz. Heterodimere özgü IL-12 antikorlari, insan IL-12 biyo-aktivitesini nötralize etme potansiyeline benzer bir potansiyell al yanakli maymum IL-12 biyo-aktivitesini nötralize eder, bu da onlari yararli IL-12 antagonistler yapar.
TR2000/02145T 1998-01-23 1999-01-15 İnsan IL-12'ye karşı antikorlar TR200002145T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7233398P 1998-01-23 1998-01-23

Publications (1)

Publication Number Publication Date
TR200002145T2 true TR200002145T2 (tr) 2000-11-21

Family

ID=22106938

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/02145T TR200002145T2 (tr) 1998-01-23 1999-01-15 İnsan IL-12'ye karşı antikorlar

Country Status (18)

Country Link
US (1) US6225117B1 (tr)
EP (2) EP1049717B1 (tr)
JP (3) JP4481489B2 (tr)
KR (1) KR100764256B1 (tr)
CN (2) CN100374466C (tr)
AR (2) AR014459A1 (tr)
AT (2) ATE357459T1 (tr)
AU (1) AU759624B2 (tr)
BR (1) BR9907743A (tr)
CA (1) CA2318052C (tr)
CY (2) CY1106594T1 (tr)
DE (1) DE69935574T2 (tr)
DK (2) DK1818343T3 (tr)
ES (2) ES2386262T3 (tr)
PT (2) PT1818343E (tr)
TR (1) TR200002145T2 (tr)
WO (1) WO1999037682A2 (tr)
ZA (1) ZA99452B (tr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003104495A1 (en) * 2002-06-11 2003-12-18 Isis Pharmaceuticals, Inc. METHODS FOR BLOCKING ADIPOCYTE DIFFERENTIATION AND TRIGLYCERIDE ACCUMULATION WITH INTERLEUKIN 12 p35 INHIBITORS
US6399379B1 (en) 1992-09-29 2002-06-04 Isis Pharmaceuticals, Inc. Antisense modulation of interleukin 12 p35 subunit expression
US6706264B1 (en) 1994-03-14 2004-03-16 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US7026456B1 (en) 1998-01-23 2006-04-11 Hoffman-La Roche, Inc. Antibodies against human IL-12
US6448081B1 (en) 2001-05-07 2002-09-10 Isis Pharmaceuticals, Inc. Antisense modulation of interleukin 12 p40 subunit expression
CA2353520C (en) * 1998-12-09 2006-04-25 Protein Design Labs, Inc. Animal model for psoriasis for the prevention and treatment of psoriasis in humans
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US6939545B2 (en) * 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
AU3495301A (en) * 2000-02-11 2001-08-20 Biogen Inc Heterologous polypeptide of the tnf family
US6348316B1 (en) 2000-04-12 2002-02-19 Cedars-Sinai Medical Center Genetic testing for determining the risk of pouchitis development
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US7638604B2 (en) * 2001-02-23 2009-12-29 Genetics Institute, Llc Monoclonal antibodies against interleukin-22
AU2002314825A1 (en) * 2001-05-30 2002-12-09 Centocor, Inc. Anti-p40 immunoglobulin derived proteins, compositions, methods and uses
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
SI1585546T1 (sl) * 2002-12-30 2008-12-31 Biogen Idec Inc KIM-1 antagonisti in uporaba za moduliranje imunskega sistema
CA2550155C (en) * 2003-12-15 2015-03-17 Dendreon Corporation Hla-dr-specific antibodies, compositions and methods
GB0329146D0 (en) * 2003-12-16 2004-01-21 Glaxosmithkline Biolog Sa Vaccine
CN101120087A (zh) 2004-12-21 2008-02-06 森托科尔公司 抗-il-12抗体、表位、组合物、方法和用途
CN103751780A (zh) 2005-03-02 2014-04-30 比奥根艾迪克Ma公司 用于治疗th2介导的疾病的kim-1抗体
MX2007016401A (es) * 2005-06-30 2008-02-20 Abbott Lab Proteinas de union il-12/p40.
TW200744634A (en) * 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
TWI417301B (zh) * 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
AU2008205512B2 (en) 2007-01-16 2014-06-12 Abbvie Inc. Methods for treating psoriasis
CN101679507A (zh) 2007-03-29 2010-03-24 艾博特公司 结晶抗人类il-12抗体
WO2009117289A2 (en) 2008-03-18 2009-09-24 Abbott Laboratories Methods for treating psoriasis
AU2009281713B9 (en) 2008-08-14 2014-05-29 Teva Pharmaceuticals Australia Pty Ltd Anti-IL-12/IL-23 antibodies
EP2350649A4 (en) * 2008-11-28 2012-11-14 Abbott Lab STABLE ANTIBODY COMPOSITIONS AND METHODS FOR STABILIZING THE SAME
RU2012114854A (ru) * 2009-09-14 2013-10-27 Эбботт Лэборетриз Способы лечения псориаза
CN103275222B (zh) * 2013-05-15 2014-04-16 中山康方生物医药有限公司 一种阻断白介素12 p40功能的单克隆抗体及其编码基因和应用
EA201892190A1 (ru) 2016-03-29 2019-04-30 Янссен Байотек, Инк. Лечение псориаза антителом к ил-12 и/или ил-23 с возрастанием интервала между введениями дозы
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
JP7421500B2 (ja) 2018-05-18 2024-01-24 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ１２／ｉｌ２３抗体でループスを治療する安全かつ有効な方法
US10961307B2 (en) 2018-09-24 2021-03-30 Janssen Biotech, Inc. Methods of treating moderately to severely active ulcerative colitis by administering an anti-IL12/IL23 antibody
CN113874073A (zh) 2019-05-23 2021-12-31 詹森生物科技公司 用针对IL-23和TNFα的抗体的联合疗法治疗炎性肠病的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811523A (en) 1988-11-10 1998-09-22 Trinchieri; Giorgio Antibodies to natural killer stimulatory factor
US6683046B1 (en) 1989-12-22 2004-01-27 Hoffmann-La Roche Inc. Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
CA2125763C (en) * 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
US5536657A (en) 1993-07-19 1996-07-16 Hoffmann-La Roche Inc. Recombinant DNA encoding human receptor for interleukin-12
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US7119248B1 (en) * 1994-04-12 2006-10-10 Miltenyi Biotec Gmbh Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
US5853721A (en) * 1995-01-31 1998-12-29 Hoffmann-La Roche Inc. Antibody to interleukin-12 receptor
US5853697A (en) * 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
US5809360A (en) * 1996-08-07 1998-09-15 Agfa Division - Bayer Corporation Cassette for storing and accessing plates within an automated plate handler
IL123888A0 (en) * 1997-04-01 1998-10-30 Sankyo Co Anti-fas antibodies

Also Published As

Publication number Publication date
WO1999037682A2 (en) 1999-07-29
ES2386262T3 (es) 2012-08-14
ATE553129T1 (de) 2012-04-15
ES2284242T3 (es) 2007-11-01
EP1049717B1 (en) 2007-03-21
AU2517799A (en) 1999-08-09
DE69935574D1 (de) 2007-05-03
CA2318052A1 (en) 1999-07-29
AU759624B2 (en) 2003-04-17
ZA99452B (en) 1999-07-23
CY1112927T1 (el) 2016-04-13
EP1049717A2 (en) 2000-11-08
JP2013139458A (ja) 2013-07-18
KR100764256B1 (ko) 2007-10-05
ATE357459T1 (de) 2007-04-15
PT1049717E (pt) 2007-05-31
AR014459A1 (es) 2001-02-28
CN100374466C (zh) 2008-03-12
WO1999037682A3 (en) 1999-11-18
PT1818343E (pt) 2012-07-12
US6225117B1 (en) 2001-05-01
DK1049717T3 (da) 2007-07-30
EP1818343A2 (en) 2007-08-15
JP2009197008A (ja) 2009-09-03
EP1818343B1 (en) 2012-04-11
CN101274962A (zh) 2008-10-01
CY1106594T1 (el) 2012-01-25
KR20010034315A (ko) 2001-04-25
DE69935574T2 (de) 2007-12-06
EP1818343A3 (en) 2007-08-22
JP2002501085A (ja) 2002-01-15
JP4481489B2 (ja) 2010-06-16
CN1288468A (zh) 2001-03-21
BR9907743A (pt) 2000-10-17
DK1818343T3 (da) 2012-07-16
CA2318052C (en) 2012-07-03
AR061801A2 (es) 2008-09-24

Similar Documents

Publication Publication Date Title
TR200002145T2 (tr) İnsan IL-12'ye karşı antikorlar
HRP20180941T1 (hr) Protutijela protiv il-17
ATE469176T1 (de) Modifizierter anti-tnf antikörper
ATE477273T1 (de) Humanisierte antikoerper gegen gamma-interferon
RS51829B (sr) Ljudska antitela specifična za interleukin 15 (il-15)
CY1112787T1 (el) Πολλαπλομερη του υποδοχεα κυτοκινης ζcytor17
RS51318B (sr) Varijante imunoglobulina i njihova upotreba
RS51180B (sr) Interleukin-10 antitela
BRPI0511910A (pt) anticorpos antil-il-13 e complexos
UA96122C2 (ru) Антитело или его антигенсвязующий фрагмент, которое специфически связывается с il-22ra, и его применение
RS52889B (sr) Terapijsko humano anti-il-1r1 monoklonsko antitelo
CY1109725T1 (el) Ειδικες δεσμευομενες πρωτεϊνες και χρησεις αυτων
NZ547157A (en) Interferon Alpha Antibodies and their uses
RS51197B (sr) Anti-dual integrinska antitela, sastavi, metode i njihove upotrebe
UA89017C2 (uk) ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
MX9704897A (es) Secuencias del anticuerpo anti-idiotipo monoclonal recombinante 3h1 relacionadas con el antigeno carcinoembrionico humano.
EA200970416A1 (ru) Полипептиды с усиленными противовоспалительными и сниженными цитотоксическими свойствами и способы, относящиеся к ним
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
TR199900267T2 (tr) GnRH-Lökotoksin kimeralari.
DK1190056T3 (da) Human cytokin receptor
WO2007117577A3 (en) High affinity human antibodies to human il-18 receptor
DK1430133T3 (da) En oplöselig Toll-lignende receptor
DK1447414T3 (da) Antagonistpeptider af carcinoembronisk antigen (CEA)
KR930012827A (ko) 항 사람 IgE 모노클로날 항체
EA201001190A1 (ru) Выделенное антитело, специфически связанное с полипептидом, состоящее из последовательности аминокислотных остатков